Keyphrases
Breast Cancer
63%
Tumor
35%
Breast Cancer Patients
31%
Trastuzumab
25%
Disease-free Survival
23%
Human Epidermal Growth Factor Receptor 2 (HER2)
21%
Overall Survival
20%
Microphthalmia-associated Transcription Factor
19%
Recurrence Score
18%
Early Breast Cancer
18%
Hazard Ratio
17%
Signal Transducer and Activator of Transcription 3
17%
Luminal Breast Cancer
16%
Adjuvant Therapy
15%
Trastuzumab Resistance
15%
Chemotherapy
15%
Human Epidermal Growth Factor Receptor 2-positive Breast Cancer
13%
Breast Cancer Susceptibility Gene 1 (BRCA1)
13%
Breast Cancer Treatment
13%
Oncotype DX
12%
HER2-positive Breast Cancer
12%
Hormone Receptor-positive
12%
Clinical Outcomes
12%
Adjuvant Trastuzumab
12%
Mast Cells
12%
BRCA2 mutation
12%
BRCA2
12%
Heparanase
12%
Randomized Phase III Trial
12%
PIK3CA mutation
11%
ALTTO
11%
Hormone Receptor-positive Breast Cancer
10%
BRCA mutation
10%
Estrogen Receptor-positive Breast Cancer
10%
HER2-positive Tumors
10%
HER2-positive
10%
HER2-positive Early Breast Cancer
9%
Breast Cancer Subtypes
9%
Triple-negative Breast Cancer
9%
Confidence Interval
9%
BRCA1, BRCA2
9%
Clinical Trials
9%
Good Prognosis
8%
Estrogen Receptor-positive
8%
Metastatic Breast Cancer
8%
Multivariable
8%
Obesity
8%
Pertuzumab
8%
Genomic Risk
7%
Clinical Risk
7%
Medicine and Dentistry
Breast Cancer
100%
Neoplasm
48%
Trastuzumab
25%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
19%
Hormone Receptor
19%
Recurrent Disease
16%
STAT3 Protein
15%
Adjuvant Therapy
13%
Estrogen Receptor
13%
Disease Free Survival
13%
Malignant Neoplasm
13%
BRCA1
12%
Cancer Therapy
11%
Overall Survival
11%
Hazard Ratio
10%
Carcinogenesis
10%
Breast Carcinoma
9%
Cohort Analysis
8%
BRCA Mutation
8%
Heparanase
8%
Clinical Trial
8%
BRCA2
7%
Chronic Hepatitis
7%
Protein Phosphorylation
7%
Organ Culture
7%
Pertuzumab
7%
Germ Cell
7%
Gamma Urogastrone
7%
Epidermal Growth Factor Receptor 2
7%
Targeted Therapy
6%
Ex Vivo
6%
Adjuvant Chemotherapy
6%
Oncologist
6%
Glycon
6%
Breast Tumor
6%
Triple Negative Breast Cancer
6%
Metastatic Carcinoma
6%
Diseases
5%
Cytokine
5%
Biological Marker
5%
Cisplatin
5%
Macrophage
5%